"rationale","instanceType","uuid:ID","id","versionIdentifier"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","1f57087f-622b-4800-9a8b-91bacbc19ba8","StudyVersion_1","2"
